Back to Search
Start Over
Cell Plasticity in a Mouse Model of Benign Prostate Hyperplasia Drives Amplification of Androgen-Independent Epithelial Cell Populations Sensitive to Antioxidant Therapy.
- Source :
-
The American journal of pathology [Am J Pathol] 2024 Jan; Vol. 194 (1), pp. 30-51. Date of Electronic Publication: 2023 Oct 10. - Publication Year :
- 2024
-
Abstract
- Benign prostate hyperplasia (BPH) is caused by the nonmalignant enlargement of the transition zone of the prostate gland, leading to lower urinary tract symptoms. Although current medical treatments are unsatisfactory in many patients, the limited understanding of the mechanisms driving disease progression prevents the development of alternative therapeutic strategies. The probasin-prolactin (Pb-PRL) transgenic mouse recapitulates many histopathological features of human BPH. Herein, these alterations parallel urodynamic disturbance reminiscent of lower urinary tract symptoms. Single-cell RNA-sequencing analysis of Pb-PRL mouse prostates revealed that their epithelium mainly includes low-androgen signaling cell populations analogous to Club/Hillock cells enriched in the aged human prostate. These intermediate cells are predicted to result from the reprogramming of androgen-dependent luminal cells. Pb-PRL mouse prostates exhibited increased vulnerability to oxidative stress due to reduction of antioxidant enzyme expression. One-month treatment of Pb-PRL mice with anethole trithione (ATT), a specific inhibitor of mitochondrial ROS production, reduced prostate weight and voiding frequency. In human BPH-1 epithelial cells, ATT decreased mitochondrial metabolism, cell proliferation, and stemness features. ATT prevented the growth of organoids generated by sorted Pb-PRL basal and LSC <superscript>med</superscript> cells, the two major BPH-associated, androgen-independent epithelial cell compartments. Taken together, these results support cell plasticity as a driver of BPH progression and therapeutic resistance to androgen signaling inhibition, and identify antioxidant therapy as a promising treatment of BPH.<br />Competing Interests: Disclosure Statement O.P. holds a patent on ATT repositioning for BPH treatment. He participated in initial study design, but had no role in data collection, analysis, and interpretation, or writing of the manuscript.<br /> (Copyright © 2024 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.)
- Subjects :
- Male
Humans
Mice
Animals
Aged
Androgens pharmacology
Androgens metabolism
Prostate pathology
Antioxidants pharmacology
Cell Plasticity
Hyperplasia pathology
Lead metabolism
Lead therapeutic use
Mice, Transgenic
Prolactin metabolism
Prolactin therapeutic use
Epithelial Cells metabolism
Prostatic Hyperplasia metabolism
Lower Urinary Tract Symptoms metabolism
Lower Urinary Tract Symptoms pathology
Subjects
Details
- Language :
- English
- ISSN :
- 1525-2191
- Volume :
- 194
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- The American journal of pathology
- Publication Type :
- Academic Journal
- Accession number :
- 37827216
- Full Text :
- https://doi.org/10.1016/j.ajpath.2023.09.010